Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for DNLI

Stock NameDenali Therapeutics Inc
TickerDNLI(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS24823R1059
LEI549300ZTQ2HO18L3Q830

Show aggregate DNLI holdings

News associated with DNLI

Financial Survey: Denali Therapeutics (NASDAQ:DNLI) & Celcuity (NASDAQ:CELC)
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) and Celcuity (NASDAQ:CELC – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations. Analyst Ratings This is a summary of current ratings […] - 2025-09-17 02:12:56
Denali Therapeutics (NASDAQ:DNLI) Receives “Overweight” Rating from Cantor Fitzgerald
Cantor Fitzgerald restated their overweight rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a research note released on Monday morning,Benzinga reports. Other research analysts have also recently issued reports about the company. TD Cowen raised Denali Therapeutics to a “strong-buy” rating in a report on Monday, July 28th. Morgan Stanley dropped their […] - 2025-09-09 02:50:44
Denali Therapeutics (NASDAQ:DNLI) Upgraded at TD Cowen
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) was upgraded by TD Cowen to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports. DNLI has been the subject of a number of other reports. Cantor Fitzgerald raised shares of Denali Therapeutics from a “neutral” rating to an “overweight” rating in a research […] - 2025-07-30 02:20:44
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of “Buy” by Brokerages
Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has received an average rating of “Buy” from the seventeen analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. […] - 2025-07-29 02:30:59
New York State Common Retirement Fund Has $955,000 Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)
New York State Common Retirement Fund decreased its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 51.5% in the first quarter, HoldingsChannel reports. The firm owned 70,240 shares of the company’s stock after selling 74,484 shares during the period. New York State Common Retirement Fund’s holdings in Denali Therapeutics were worth $955,000 at […] - 2025-07-25 04:56:54
DekaBank Deutsche Girozentrale Raises Position in Denali Therapeutics Inc. (NASDAQ:DNLI)
DekaBank Deutsche Girozentrale raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 7.4% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 64,210 shares of the company’s stock after acquiring an additional 4,410 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Denali Therapeutics were worth $935,000 as of its most […] - 2025-07-14 06:44:51
Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Ryan J. Watts Sells 495,282 Shares
Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) CEO Ryan J. Watts sold 495,282 shares of Denali Therapeutics stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total value of $7,429,230.00. Following the completion of the transaction, the chief executive officer owned 253,071 shares […] - 2025-07-14 05:10:49
LABU's Holdings Imply 58% Gain Potential
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-10 07:59:01
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $33.71 Average PT from Brokerages
Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has earned an average recommendation of “Buy” from the seventeen research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating […] - 2025-06-12 02:28:50
Analysts Anticipate VB To Hit $270
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-09 08:43:39
Two Sigma Advisers LP Acquires Shares of 15,100 Denali Therapeutics Inc. (NASDAQ:DNLI)
Two Sigma Advisers LP acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 15,100 shares of the company’s stock, valued at approximately $308,000. Other hedge funds also recently bought […] - 2025-06-06 05:12:49
Squarepoint Ops LLC Purchases 14,896 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)
Squarepoint Ops LLC grew its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 44.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,619 shares of the company’s stock after buying an additional 14,896 shares during the quarter. Squarepoint […] - 2025-06-01 05:31:11
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 3,411 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 4.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 85,075 shares of the company’s stock after purchasing an additional 3,411 shares during […] - 2025-05-23 06:26:52
Janus Henderson Group PLC Purchases 7,900 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)
Janus Henderson Group PLC grew its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 15.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 60,028 shares of the company’s stock after purchasing an additional 7,900 shares during the quarter. Janus Henderson Group PLC’s […] - 2025-05-23 05:26:51
Bank of America Cuts Denali Therapeutics (NASDAQ:DNLI) Price Target to $27.00
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its price objective reduced by research analysts at Bank of America from $28.00 to $27.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price objective suggests a potential upside of 88.94% from the stock’s current […] - 2025-05-21 02:56:58
Deutsche Bank AG Buys 37,907 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)
Deutsche Bank AG boosted its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 15.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 277,853 shares of the company’s stock after purchasing an additional 37,907 shares during the period. Deutsche Bank AG’s holdings in Denali Therapeutics were worth $5,663,000 as of its most […] - 2025-05-19 05:06:53
Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Bought by Northern Trust Corp
Northern Trust Corp grew its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,201,518 shares of the company’s stock after acquiring an additional 115,876 shares during the […] - 2025-05-13 05:28:54
Denali Therapeutics (NASDAQ:DNLI) Trading Down 10.1% Following Weak Earnings
Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report)’s stock price was down 10.1% on Tuesday following a dissappointing earnings announcement. The stock traded as low as $14.41 and last traded at $14.38. Approximately 525,609 shares changed hands during trading, a decline of 52% from the average daily volume of 1,084,610 shares. The stock had previously […] - 2025-05-08 03:08:47
Dimensional Fund Advisors LP Has $37.81 Million Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI)
Dimensional Fund Advisors LP lifted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 19.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,855,036 shares of the company’s stock after purchasing an additional 295,594 shares during the period. […] - 2025-05-05 05:20:52
Sterling Capital Management LLC Has $36,000 Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)
Sterling Capital Management LLC raised its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 589.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,773 shares of the company’s stock after purchasing an additional 1,516 shares during the quarter. Sterling […] - 2025-04-25 05:34:52
Franklin Resources Inc. Decreases Position in Denali Therapeutics Inc. (NASDAQ:DNLI)
Franklin Resources Inc. reduced its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 6.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,862 shares of the company’s stock after selling 5,179 shares during the period. […] - 2025-04-15 04:56:57
Pictet Asset Management Holding SA Grows Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)
Pictet Asset Management Holding SA raised its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 17.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,356 shares of the company’s stock after buying an additional 2,806 shares during the […] - 2025-04-10 05:37:07
Sei Investments Co. Lowers Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI)
Sei Investments Co. decreased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 8.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 24,047 shares of the company’s stock after selling 2,229 shares during the quarter. Sei Investments Co.’s holdings in Denali Therapeutics were worth $490,000 at the end of the […] - 2025-04-10 04:18:49
1,065,608 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Norges Bank
Norges Bank bought a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,065,608 shares of the company’s stock, valued at approximately $21,717,000. Several other hedge funds also recently made changes to their […] - 2025-04-07 04:51:10
Schroder Investment Management Group Has $5.02 Million Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)
Schroder Investment Management Group increased its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 94.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 247,800 shares of the company’s stock after purchasing an additional 120,494 shares during the […] - 2025-04-06 05:29:07
Corebridge Financial Inc. Sells 4,665 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)
Corebridge Financial Inc. lowered its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 7.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,800 shares of the company’s stock after selling 4,665 shares during the quarter. […] - 2025-04-04 05:09:15
American Century Companies Inc. Buys 29,155 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)
American Century Companies Inc. raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 6.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 480,529 shares of the company’s stock after buying an additional 29,155 shares during the period. American Century Companies Inc.’s […] - 2025-04-03 04:32:51
Teacher Retirement System of Texas Purchases 5,987 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)
Teacher Retirement System of Texas grew its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 18.6% in the 4th quarter, Holdings Channel reports. The fund owned 38,178 shares of the company’s stock after buying an additional 5,987 shares during the period. Teacher Retirement System of Texas’ holdings in Denali Therapeutics were […] - 2025-03-31 05:00:58
Cibc World Markets Corp Purchases Shares of 11,633 Denali Therapeutics Inc. (NASDAQ:DNLI)
Cibc World Markets Corp acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,633 shares of the company’s stock, valued at approximately $237,000. Other large investors have also modified their holdings […] - 2025-03-26 06:09:01
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eighteen research firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and one has assigned a strong buy […] - 2025-03-26 04:26:42

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) DNLI holdings

DateNumber of DNLI Shares HeldBase Market Value of DNLI SharesLocal Market Value of DNLI SharesChange in DNLI Shares HeldChange in DNLI Base ValueCurrent Price per DNLI Share HeldPrevious Price per DNLI Share Held
2025-11-12 (Wednesday)94,075USD 1,648,194USD 1,648,194
2025-11-11 (Tuesday)93,834USD 1,649,602DNLI holding increased by 185792USD 1,649,6020USD 185,792 USD 17.58 USD 15.6
2025-11-10 (Monday)93,834DNLI holding increased by 240USD 1,463,810DNLI holding increased by 58028USD 1,463,810240USD 58,028 USD 15.6 USD 15.02
2025-11-07 (Friday)93,594USD 1,405,782DNLI holding increased by 57092USD 1,405,7820USD 57,092 USD 15.02 USD 14.41
2025-11-06 (Thursday)93,594DNLI holding increased by 240USD 1,348,690DNLI holding decreased by -41351USD 1,348,690240USD -41,351 USD 14.41 USD 14.89
2025-11-05 (Wednesday)93,354USD 1,390,041DNLI holding decreased by -2801USD 1,390,0410USD -2,801 USD 14.89 USD 14.92
2025-11-04 (Tuesday)93,354DNLI holding increased by 241USD 1,392,842DNLI holding decreased by -37374USD 1,392,842241USD -37,374 USD 14.92 USD 15.36
2025-11-03 (Monday)93,113USD 1,430,216DNLI holding decreased by -85664USD 1,430,2160USD -85,664 USD 15.36 USD 16.28
2025-10-31 (Friday)93,113USD 1,515,880DNLI holding decreased by -9311USD 1,515,8800USD -9,311 USD 16.28 USD 16.38
2025-10-30 (Thursday)93,113DNLI holding increased by 1205USD 1,525,191DNLI holding increased by 31686USD 1,525,1911,205USD 31,686 USD 16.38 USD 16.25
2025-10-29 (Wednesday)91,908DNLI holding increased by 482USD 1,493,505DNLI holding decreased by -53423USD 1,493,505482USD -53,423 USD 16.25 USD 16.92
2025-10-28 (Tuesday)91,426USD 1,546,928DNLI holding increased by 64913USD 1,546,9280USD 64,913 USD 16.92 USD 16.21
2025-10-27 (Monday)91,426USD 1,482,015DNLI holding increased by 22856USD 1,482,0150USD 22,856 USD 16.21 USD 15.96
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of DNLI by Blackrock for IE00BYXG2H39

Show aggregate share trades of DNLI

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-10BUY24016.55515.325 15.448USD 3,708 17.46
2025-11-06BUY24015.10014.300 14.380USD 3,451 17.49
2025-11-04BUY24115.29014.830 14.876USD 3,585 17.51
2025-10-30BUY1,20516.98016.000 16.098USD 19,398 17.54
2025-10-29BUY48216.25016.980 16.907USD 8,149 17.54
2025-10-22SELL-96415.95017.260 17.129USD -16,512 17.58 Profit of 436 on sale
2025-10-20BUY48217.25017.720 17.673USD 8,518 17.59
2025-10-17BUY1,20416.66016.800 16.786USD 20,210 17.59
2025-10-15BUY1,92016.31016.430 16.418USD 31,523 17.60
2025-10-03BUY1,69415.42015.750 15.717USD 26,625 17.62
2025-10-02BUY24215.20015.680 15.632USD 3,783 17.64
2025-09-30BUY48414.52014.580 14.574USD 7,054 17.67
2025-09-26BUY48413.95014.070 14.058USD 6,804 17.71
2025-09-25BUY48413.43013.600 13.583USD 6,574 17.74
2025-09-24SELL-3,15213.48013.650 13.633USD -42,971 17.76 Profit of 13,010 on sale
2025-09-18BUY25113.18013.490 13.459USD 3,378 17.79
2025-09-17BUY75613.06013.860 13.780USD 10,418 17.82
2025-08-20SELL-1,00014.51014.840 14.807USD -14,807 17.89 Profit of 3,086 on sale
2025-07-30BUY1,00013.67014.710 14.606USD 14,606 18.03
2025-07-17SELL-50014.53015.150 15.088USD -7,544 18.28 Profit of 1,594 on sale
2025-07-11SELL-2,00014.52015.350 15.267USD -30,534 18.38 Profit of 6,219 on sale
2025-07-07BUY75014.25014.670 14.628USD 10,971 18.48
2025-07-02BUY13,80514.90015.000 14.990USD 206,937 18.53
2025-06-20BUY1,88913.89014.130 14.106USD 26,646 18.56
2025-06-11BUY49015.19015.690 15.640USD 7,664 18.78
2025-06-10BUY49015.26015.620 15.584USD 7,636 18.80
2025-06-04SELL-24514.42014.670 14.645USD -3,588 18.94 Profit of 1,052 on sale
2025-04-23BUY24414.87015.590 15.518USD 3,786 20.29
2025-04-10SELL-1,95212.50012.970 12.923USD -25,226 21.03 Profit of 15,821 on sale
2025-04-08SELL-24411.47012.480 12.379USD -3,020 21.23 Profit of 2,160 on sale
2025-04-07SELL-24411.60011.870 11.843USD -2,890 21.34 Profit of 2,318 on sale
2025-04-04SELL-1,22511.78012.630 12.545USD -15,368 21.46 Profit of 10,916 on sale
2025-04-01BUY2,67312.29013.670 13.532USD 36,171 21.66
2025-03-31SELL-71713.59514.390 14.311USD -10,261 21.76 Profit of 5,340 on sale
2025-03-21BUY3,73214.43014.640 14.619USD 54,558 22.34
2025-03-14SELL-3,63215.15015.700 15.645USD -56,823 22.87 Profit of 26,228 on sale
2025-03-07SELL-45416.69016.970 16.942USD -7,692 23.42 Profit of 2,943 on sale
2025-03-04SELL-22715.95016.500 16.445USD -3,733 23.77 Profit of 1,663 on sale
2025-02-25BUY45419.20020.830 20.667USD 9,383 24.29
2025-02-19SELL-22622.23022.270 22.266USD -5,032 24.51 Profit of 508 on sale
2025-02-13BUY67821.31021.540 21.517USD 14,589 24.76
2025-02-12BUY22620.82021.030 21.009USD 4,748 24.84
2025-02-11BUY90420.58021.510 21.417USD 19,361 24.93
2024-12-30SELL-7,26720.24020.510 20.483USD -148,850 26.03 Profit of 40,297 on sale
2024-11-18SELL-3,67524.18025.350 25.233USD -92,731 27.61 Profit of 8,722 on sale
2024-11-08SELL-24531.35031.460 31.449USD -7,705 27.18 Loss of -1,047 on sale
2024-10-21SELL-24526.38027.490 27.379USD -6,708 0.00 Loss of -6,708 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of DNLI

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19378,1591,201906,79941.7%
2025-09-18267,7057,938845,21031.7%
2025-09-17409,8617001,166,91035.1%
2025-09-16391,4953001,419,69727.6%
2025-09-15260,6650671,93738.8%
2025-09-12206,5700814,13725.4%
2025-09-11275,762207657,64941.9%
2025-09-10329,3340769,46042.8%
2025-09-09309,1050685,69045.1%
2025-09-08379,188581,067,13235.5%
2025-09-05349,05902,670,12813.1%
2025-09-04280,93711,807555,93150.5%
2025-09-03417,11301,357,89530.7%
2025-09-02422,8855,2053,059,39813.8%
2025-08-29549,1503991,42655.4%
2025-08-28543,2797501,001,43854.2%
2025-08-27366,4270654,68656.0%
2025-08-26644,04801,095,69658.8%
2025-08-25291,7840587,61749.7%
2025-08-22312,5542001,397,37122.4%
2025-08-21399,0820875,60745.6%
2025-08-20326,1840625,31752.2%
2025-08-19264,8630410,14164.6%
2025-08-18309,6690516,16360.0%
2025-08-15209,5600463,25645.2%
2025-08-14332,064232818,15240.6%
2025-08-13524,4520992,83852.8%
2025-08-12325,3181,582713,95745.6%
2025-08-11295,5850597,42849.5%
2025-08-08698,45101,028,93567.9%
2025-08-07587,3230987,05159.5%
2025-08-06756,41301,219,50362.0%
2025-08-05416,20026,5981,111,99037.4%
2025-08-04474,241500928,76651.1%
2025-08-01365,6410787,31546.4%
2025-07-31376,07266896,40342.0%
2025-07-30509,9618956,41753.3%
2025-07-29282,88812622,53745.4%
2025-07-28292,3510614,15247.6%
2025-07-25234,2670458,04151.1%
2025-07-24289,89984723,17640.1%
2025-07-23345,904711676,12951.2%
2025-07-22228,07998411,31555.5%
2025-07-21237,8200416,45357.1%
2025-07-18226,5110419,95953.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.